Phreesia (PHR) — Compensation Restructuring Analysis
PFC Internal | Confidential | March 2026
$50-84M
Optimization Potential
1 Executive Summary
Key Findings
- Phreesia is a $420M-revenue healthcare SaaS company trading at ~$730M market cap (down 85% from peak) despite turning Adj. EBITDA positive ($37M) and approaching GAAP profitability
- $50-84M in annual cost optimization potential that management is pursuing on their own timeline but could accelerate by 12-24 months under restructured incentives
- Comp committee is being fully reconstituted in mid-2026; Jon Kessler (pay-for-performance purist from HealthEquity) joining the board
- Recommendation: Option B (Moderate) — restructure PSU metrics, add efficiency incentives, grant Transformation RSUs at current depressed prices
PFC Thesis
The stock reflects legacy valuation compression, not operational reality. We see $50-84M in annual cost optimization potential. The comp committee reconstitution and Kessler's arrival create a rare window to align incentives with the efficiency trajectory management has already started.
Why Comp Restructuring Now
| # | Catalyst | Detail |
|---|
| 1 | Comp committee turnover | Both veterans (Weintraub, Cahill) depart simultaneously at 2026 Annual Meeting |
| 2 | Kessler arrives | Pay-for-performance purist; ISS QualityScore 1 at HealthEquity; 85-90% equity comp philosophy |
| 3 | PSU weakness | Current PSUs are 100% relative TSR vs. Russell 3000 — no operational component |
| 4 | SBC drag | GAAP-to-Adj. EBITDA gap is almost entirely SBC ($67-95M/year, 16-23% of revenue) |
| 5 | R&D opportunity | R&D at 28% of revenue (vs. 20-22% benchmark) is the biggest optimization target, but nothing in comp incentivizes efficiency |
Three Key Action Items
Action Items & Timeline
1. Now – May 2026: Engage CFO Gandhi informally. Present PFC's perspective on comp evolution. No formal proposal yet.
2. Apr – Jun 2026: After Kessler joins (April 6), seek informal conversation. Test receptivity to HealthEquity-style operational metrics in PSUs.
3. Jul – Sep 2026: After Annual Meeting and new comp committee is seated, submit formal Option B proposal through Gandhi to the comp committee.
2 Company Deep Dive
Key Findings
- Revenue 5x since IPO ($100M to $480M+) with 99% client retention
- $130M EBITDA swing in 2 years (from -$92.5M to +$37M) without external pressure
- R&D at 28% of revenue is 6-8pp above at-scale SaaS benchmarks — the single largest optimization target
- SBC at 16% of revenue is the elephant in the room between adjusted and GAAP profitability
2a. Revenue Segments
| Segment | FY2023 | FY2024 | FY2025 | YoY | Mix |
|---|
| Subscription & Related Services | ~$131M | $165M | $197M | +19% | 47% |
| Payment Processing Fees | ~$80M | $95M | $102M | +8% | 24% |
| Network Solutions | ~$70M | $96M | $122M | +26% | 29% |
| Total Revenue | $280.9M | $356.3M | $419.8M | +18% | 100% |
2b. P&L Waterfall
| Line Item | FY2023 | % Rev | FY2024 | % Rev | FY2025 | % Rev |
|---|
| Revenue | $280.9M | 100% | $356.3M | 100% | $419.8M | 100% |
| Total Cost of Revenue | $109.3M | 39% | $124.0M | 35% | $134.9M | 32% |
| Gross Profit | $171.6M | 61% | $232.3M | 65% | $284.9M | 68% |
| Sales & Marketing | ~$141M | 50% | ~$147M | 41% | ~$121M | 29% |
| R&D | $91.2M | 32% | $112.3M | 32% | $117.4M | 28% |
| G&A | ~$80.4M | 29% | ~$79.9M | 22% | ~$76.6M | 18% |
| Operating Loss | ($176.6M) | -63% | ($136.5M) | -38% | ($58.1M) | -14% |
2c. Cost Structure Teardown — The $50-84M Opportunity
| Category | FY2025 ($M) | % Revenue | Target % | Savings Potential |
|---|
| Sales & Marketing | $121 | 29% | 22% | $15-26M |
| R&D | $117 | 28% | 22% | $21-33M |
| G&A | $77 | 18% | 15% | $8-15M |
| Cost of Revenue | $135 | 32% | 30% | $6-10M |
| Total Opex | $450 | 107% | 89% | $50-84M |
2d. Margin Expansion Scenarios
| Scenario | FY2026E Revenue | EBITDA Margin | EBITDA ($M) | vs. Guided |
|---|
| Management Plan | $477M | 17-19% | $81-91M | Baseline |
| Conservative (Option A) | $477M | 22-24% | $105-115M | +$24M |
| Moderate (Option B) | $477M | 27-30% | $129-143M | +$48-52M |
| Aggressive (Option C) | $477M | 32-35% | $153-167M | +$72-76M |
2e. 3-Year P&L Under Option B
| Metric | FY2025 Actual | FY2027E | FY2028E |
|---|
| Revenue | $420M | $545-559M | $620-650M |
| Gross Margin | 68% | 70% | 72% |
| R&D % Revenue | 28% | 24% | 22% |
| S&M % Revenue | 29% | 22% | 20% |
| G&A % Revenue | 18% | 15% | 14% |
| Adj. EBITDA Margin | 9% | 24-27% | 30-33% |
| SBC % Revenue | 16% | 12% | 10% |
| GAAP Net Income | ($58.5M) | $20-40M | $60-90M |
2f. Earnings Call Theme Analysis
| Quarter | Revenue | EBITDA | AHSCs | Key Theme |
|---|
| Q1 FY23 | $63.4M | ~($23M) | ~2,530 | Post-investment operating leverage starting |
| Q2 FY23 | $67.9M | ~($23M) | ~2,776 | Cash burn concerns; guidance maintained |
| Q3 FY23 | $73.1M | ($18.3M) | 2,982 | Client growth 42% YoY |
| Q4 FY23 | $76.6M | ($17.6M) | 3,140 | 8th consecutive 30%+ growth quarter |
| Q1 FY24 | $83.9M | ($13.8M) | 3,309 | Gandhi appointed CFO; EBITDA improving |
| Q2 FY24 | $85.8M | ($11.5M) | 3,445 | EBITDA guidance raised |
| Q3 FY24 | $91.6M | ($6.6M) | 3,688 | EBITDA guidance raised again |
| Q4 FY24 | $95.0M | ($3.5M) | 3,962 | Near breakeven |
| Q1 FY25 | $101.2M | $4.1M | ~4,065 | First positive EBITDA in 3 years |
| Q2 FY25 | $102.1M | $6.5M | 4,169 | First positive FCF |
| Q3 FY25 | $106.8M | $9.8M | 4,237 | FY26 outlook introduced |
| Q4 FY25 | $109.7M | $16.4M | 4,341 | Strong momentum |
| Q1 FY26 | $115.9M | $20.8M | 4,411 | EBITDA guidance raised to $85-90M |
| Q2 FY26 | $117.3M | $22.0M | 4,467 | First GAAP net income ($0.7M) |
| Q3 FY26 | $120.3M | $29.1M | 4,520 | AccessOne closed ($160M) |
| Fiscal Year | Initial Revenue Guidance | Outcome | Result |
|---|
| FY2023 | $271-275M | $280.9M | Beat |
| FY2024 | $353-356M | $356.3M | Met (top) |
| FY2025 | $424-434M (revised to $416-426M) | $419.8M | Met (mid-range) |
| FY2026 | $472-482M | Tracking $479-481M | On pace |
EBITDA guidance raised every quarter for 3 consecutive fiscal years. Conservative initial guidance with built-in upside — a credibility-building approach.
CEO Indig explicitly resists AI hype: "Clients don't buy AI. What they buy is solutions to really complex problems."
Products launched: VoiceAI (conversational AI for call management), ML for claims (predictive denial models), AI referral tools (MediFind). Currently at no cost; monetization follows adoption (historical pattern).
Analyst skepticism: Unclear monetization timeline, vague AI investment allocation, evolving scope without clear roadmap, no concrete revenue projections for AI products.
2g. Key Operating Metrics
| Metric | FY2023 | FY2024 | FY2025 | Trend |
|---|
| Avg Healthcare Services Clients (AHSCs) | 2,864 | 3,601 | 4,203 | +17% YoY |
| Revenue per AHSC | ~$98.1K | $98.9K | $99.9K | +1% YoY (inflecting) |
| Patient Payment Volume | ~$3.4B | ~$3.9B | $4.4B | +12% YoY |
| Client Retention Rate | ~99% | ~99% | 99% | Stable |
| Revenue per Employee | ~$148K | ~$178K | ~$210K | +42% (still below $300K+ benchmark) |
| Employees | ~1,900 | ~2,000 | ~2,000 | Flat |
| Metric | Phreesia FY2025 | Best-in-Class SaaS | Gap |
|---|
| Gross Margin | 68% | 75-80% | -7-12pp |
| R&D % Revenue | 28% | 18-22% | +6-10pp |
| S&M % Revenue | 29% | 20-25% | +4-9pp |
| Adj. EBITDA Margin | 9% | 25-35% | -16-26pp |
| Revenue/Employee | $210K | $300-400K | -$90-190K |
| SBC % Revenue | 16% | 8-12% | +4-8pp |
3 Leadership & Governance
Key Findings
- Co-founders Indig/Roberts have 21 years at Phreesia — deep commitment but also potential entrenchment risk
- CFO Gandhi (ex-Deutsche Bank sell-side) is the critical point of contact — will evaluate proposals through investor lens
- Kessler's arrival is the catalyst — his "only paying for demonstrable performance" philosophy maps directly to PFC's goals
- Comp committee loses both veterans simultaneously — rare structural opportunity
3a. C-Suite Profiles
Age: 47 | Comp (FY2025): $10.5M total ($515K salary + $10.0M stock awards, ~95% equity)
Philosophy: Growth-to-profitability transition leader. Led $130M EBITDA swing. Named Top 50 CEOs (Software Report) three times. M&A-driven expansion ($160M AccessOne). AI stance: "Clients don't buy AI."
Proposal relevance: 21-year tenure signals deep commitment. Almost entirely equity-based comp is a positive alignment signal. May view operational PSU metrics as too prescriptive for a founder-CEO.
Age: ~47 | BS Computer Engineering, Tufts. Previously Spotfire (TIBCO).
Career at PHR: CTO → VP Customer Solutions → COO → President Provider Solutions. Controls product and customer-facing organization.
Proposal relevance: Low public profile, operationally focused. As co-founder with equal tenure, his comp package will be closely watched.
Age: 52 | Master's Health Services Admin, GWU. Former sell-side analyst at Deutsche Bank, Oppenheimer covering healthcare services. Then IR/corp dev at Press Ganey, Fresenius. Joined Phreesia pre-IPO 2019 as SVP IR.
Proposal relevance: Critical contact Gandhi is the gatekeeper to the board. Sell-side background means he knows what institutional shareholders want. Analytical, metrics-driven. Approach with data, not ideology.
10+ years at Phreesia. BS Mathematics (Alberta), PhD candidate Mathematics & Logic (CUNY). Responsible for life sciences partnerships — the highest-margin, fastest-growing segment (Network Solutions, 29% of revenue).
3b. Board Composition
| Director | Age | Ind. | Since | Committees | Status |
|---|
| Michael Weintraub (Chair) | 67 | Yes | 2004 | Comp (Chair), Governance, Nominating | Retiring 2026 |
| Edward L. Cahill | 73 | Yes | 2007 | Compensation | Retiring 2026 |
| Chaim Indig | 47 | No | 2004 | — | Continuing |
| Gillian Munson | 55 | Yes | 2020 | Audit (Chair), Compensation | Continuing |
| Mark Smith, M.D. | 74 | Yes | 2018 | Governance (Chair), Nominating (Chair) | Continuing |
| Lainie Goldstein | 58 | Yes | 2020 | Audit | Continuing |
| Ramin Sayar | 53 | Yes | 2021 | Audit | Continuing |
| Lisa Egbuonu-Davis, M.D. | 68 | Yes | 2023 | Comp, Governance, Nominating | Continuing |
| Jon Kessler | — | Yes | Apr 2026 | TBD | Incoming |
3c. Post-Transition Comp Committee (Likely)
| Member | Background | PFC Alignment |
|---|
| Gillian Munson (likely Chair) | Duolingo CFO, ex-Morgan Stanley | High — financial sophistication, understands comp optics |
| Lisa Egbuonu-Davis | Sanofi/Pfizer VP | Moderate — pharma comp norms, less SaaS-specific |
| Jon Kessler (highly likely) | HealthEquity CEO/founder | High — pay-for-performance purist, 85-90% equity, operational metrics in LTI |
3d. Jon Kessler Deep Dive
| Period | Role | Key Achievement |
|---|
| Early career | Senior economist, Clinton/Bush Sr. administrations | Employee benefits & environmental taxation |
| 2000-2007 | Founder, Chairman, CEO of WageWorks | $0 to ~$100M revenue; Inc. 500 three years; NYSE-listed |
| 2014-2024 | President & CEO, HealthEquity | Scaled to ~$10B enterprise value; oversaw $2B WageWorks acquisition |
| Jan 2025 | Retired from HealthEquity CEO | Transitioned to Special Advisor |
| Apr 2026 | Phreesia Board member | Effective April 6, 2026 |
HealthEquity Comp Philosophy (The Template)
- "Overarching philosophy of only paying for demonstrable performance"
- No pension, no deferred comp, no tax gross-ups for executives
- Bonus: Revenue + Adjusted EBITDA + New HSA Sales (each 33%)
- PRSUs: 75% rTSR + 25% cumulative NI/share
- CEO comp 85-90% equity (FY2024: $13.4M total, 89% equity)
- ISS Governance Compensation QualityScore: 1 (best possible)
- Exercised downward discretion on bonus (135% calculated, paid 130%)
3e. Management Quality Assessment
Case FOR Co-Founders
- Revenue 5x since IPO with 99% client retention
- $130M EBITDA swing in 2 years without external pressure
- Conservative guidance with consistent beats — 3 consecutive fiscal years
- Low-drama culture: single CFO change in 4 years, C-suite tenure 10+ years
- Already equity-heavy comp (95% CEO)
- Voluntary bonus-to-RSU at 15% premium — unique among all peers
Case AGAINST Co-Founders
- Revenue/employee at $210K vs. $300-400K best-in-class
- R&D grew 29% while S&M was cut 15% — invested rather than optimized
- CEO AI stance ("Clients don't buy AI") is pragmatic but not transformative
- AccessOne ($160M) shows M&A instinct over margin optimization
- No signals of openness to external comp restructuring
- Growth decelerating (32% to 14-16%) with no public re-acceleration plan
Net Assessment
The co-founders are competent operators executing a credible transition to profitability on their own timeline. They are not going to lead an AI-first cost revolution voluntarily. The right approach is aligning their incentives with the efficiency trajectory they've already started — not replacing them.
4 Current Compensation Analysis
Key Findings
- CEO comp ~95% equity with salary frozen 4 years — genuinely aligned
- PSUs are 100% relative TSR vs. Russell 3000 — a blunt instrument with no operational component
- Bonus-to-RSU election at 15% premium is unique among all peers studied — an innovative alignment tool
- Realized pay is very low — stock down 85%, FY2022 PSU cycle paid only 53.5%
4a. CEO Compensation Trend (FY2022-FY2025)
| Component | FY2022 | FY2023 | FY2024 | FY2025 |
|---|
| Base Salary | $515,000 | $515,000 | $495,027* | $515,000 |
| Stock Awards | $8,191,163 | $7,089,450 | $7,778,280 | $9,996,050 |
| Cash Bonus | $215,064 | $0† | $0† | $0† |
| Total Comp | $8,921,227 | $7,604,450 | $8,273,308 | $10,511,050 |
*FY2024 reflects pay-period timing. †Elected 100% of earned bonus as RSUs at 15% premium.
4b. All NEO Compensation (FY2025)
| NEO | Salary | Target Bonus | Earned (129.1%) | Bonus Election | Stock Awards | Total |
|---|
| Chaim Indig (CEO) | $515K | $515K (100%) | $664,865 | 100% RSU | $9,996,050 | $10,511,050 |
| Balaji Gandhi (CFO) | $400K | $300K (75%) | $387,300 | 100% RSU | $4,119,429 | $4,519,429 |
| Evan Roberts (COO) | $400K | $300K (75%) | $387,300 | 100% RSU | $4,119,429 | $4,519,429 |
| David Linetsky (SVP) | $400K | $300K (75%) | $387,300 | 50/50 | $3,896,713 | $4,494,053 |
| Allison Hoffman (GC) | $350K | $250K (71%) | $322,750 | 100% RSU | $2,617,637 | $2,967,637 |
4c. Compensation Structure Detail
| Feature | Detail |
|---|
| Metric | Relative TSR vs. Russell 3000 Index |
| Period | 3-year cliff vest (50% at 2.5yr, 50% at 3yr) |
| Threshold | 20th percentile = 35% payout |
| Target | 55th percentile = 100% payout |
| Maximum | 90th percentile = 220% payout |
| Negative TSR cap | If absolute 3yr TSR is negative, max payout = 100% |
| Pricing | 60-day VWAP at grant |
| NEO | PSU % | RSU % | Target Equity Value |
|---|
| CEO (Indig) | 80% | 20% | $5,000,000 |
| CFO (Gandhi) | 50% | 50% | $2,300,000 |
| COO (Roberts) | 50% | 50% | $2,300,000 |
| SVP (Linetsky) | 50% | 50% | $2,300,000 |
| GC (Hoffman) | 35% | 65% | $1,525,000 |
4d. Comp Gap Analysis
| Element | Current Structure | Assessment |
|---|
| CEO Salary | $515K, frozen 4 years | Good Below peer median, signals discipline |
| Bonus Metrics | Revenue (50%) + EBITDA (50%) | Adequate Standard two-metric plan |
| Bonus Cap | 150% | Low HealthEquity uses 200%; may demotivate outperformance |
| Bonus RSU Election | 100% to RSU at 15% premium, 1-year hold | Excellent Unique among all peers |
| PSU Metrics | 100% Relative TSR vs. Russell 3000 | Weak No operational component; broad index is poor benchmark |
| PSU Payout Range | 35-220% | Acceptable |
| Negative TSR Cap | Max 100% if absolute TSR negative | Excellent Best-in-class governance |
| RSU Vesting | Back-weighted 10/20/30/40 over 4 years | Good Strong retention mechanism |
| Equity Mix (CEO) | 80% PSU / 20% RSU | Good Above median PSU weighting |
| CIC Treatment | Double-trigger + 50% auto-vest on event | Slightly generous 50% auto-vest without termination is unusual |
| Say-on-Pay | 90.6% (2025) | Adequate Below Health Catalyst (99%) |
4e. What's Missing
Critical Gaps
- Operational metrics in LTI. PSUs are purely TSR-based. HealthEquity uses 75% TSR + 25% NI/share. Phreesia's PSUs reward market sentiment, not management execution.
- Efficiency incentives. Nothing rewards R&D optimization, revenue/employee improvement, or SBC reduction.
- Custom peer group. Russell 3000 includes energy, financials, industrials — irrelevant comparators.
- Transformation-specific grants. No mechanism to reward closing the gap between operational reality and stock price.
- Broader equity participation. Equity concentrated in NEOs; extending to top 50 Director+ employees would align broader team.
4f. Severance & CIC Provisions
| Scenario | CEO | Other NEOs |
|---|
| Termination Without Cause (no CIC) | 18 mo salary + pro-rata bonus + 18 mo equity acceleration + COBRA = $2,885,548 | 12 mo salary + pro-rata bonus + 12 mo equity accel + COBRA = $1.4-1.7M |
| CIC Termination | 2x (salary + target bonus) + 100% equity acceleration + COBRA = $5,445,575 | 1.5x (salary + target bonus) + 100% accel + COBRA = $3.4-3.9M |
Upon CIC event (regardless of termination): 50% of time-based equity accelerates immediately. No tax gross-ups. NYSE-compliant clawback.
4g. Governance Features
| Feature | Status |
|---|
| Stock ownership (CEO) | 6x base = $3,090,000 |
| Clawback policy | NYSE-compliant |
| Anti-hedging/pledging | Prohibited |
| Perquisites | None beyond standard benefits |
| Pension/deferred comp | None |
| Comp consultant | FW Cook, Inc. (independent) |
4h. Peer Group (21 companies)
8x8, A10 Networks, Accolade, Alarm.com, Bandwidth, Digital Turbine, E2open Parent, Health Catalyst, HealthEquity, Intapp, Jamf, LivePerson, LiveRamp, MultiPlan, N-able, PagerDuty, Progress Software, PROS Holdings, Q2 Holdings, Verint Systems, Zuora
5 Groupon CEO Comp Reference
Key Findings
- Premium-priced options (78% premium over FMV) at sign-on delivered 10x return — powerful alignment device
- Below-market salary ($19K, later $150K) drove say-on-pay from 73% to 98%
- 3-year option expiry creates dangerous retention cliff — avoid this at Phreesia
- Pure stock-price PSU hurdles are too noisy; proposed LTIP correctly adds FCF and rTSR
5a. Senkypl Grant History
| Year | Salary | Stock Awards | Option Awards | Total |
|---|
| FY2023 | $14,028 | $0 | $3,325,000 | $3,339,028 |
| FY2024 | $103,477 | $18,943,753 | $0 | $19,057,618 |
3,500,000 options at $6.00 strike (FMV ~$3.37 = 78% premium). Quarterly vesting over 2 years. 3-year term expiring March 2026. At ~$16 current price: deeply in-the-money, ~$35M total potential value on $3.3M grant-date value (10x return).
1,393,948 PSUs with stock price hurdles: Tranche 1 ($14.86 — achieved), Tranche 2 ($20.14), Tranche 3 ($31.01), Tranche 4 ($68.82). Service condition: 33%/33%/34% over 3 years. ~75% of PSU grant may be worthless, creating retention risk.
5b. What Worked / What Didn't
What Worked
- Premium-priced options: zero value unless stock appreciates meaningfully — 10x return validated
- Below-market salary: powerful alignment signal, say-on-pay 73% → 98%
- Simple, clean structure: no RSUs, no complex matrices, no perquisites
What Didn't Work
- 3-year option term creates cliff — March 2026 expiry forces exercise and potential selling
- PSU hurdles too aggressive: only 1 of 4 tranches achieved; 75% potentially worthless
- No operational metrics in equity — purely market-driven incentive
- No annual equity refresh — lumpy grants create retention gaps
- Annual bonus nearly worthless ($10,388 on $150K target)
5c. Proposed 2026 LTIP Structure
| Element | Tier 1: Standard PSU | Tier 2: Moonshot PSU |
|---|
| Metrics | 50% rTSR + 50% FCF | 50% Revenue $1B + 50% Stock $68 |
| Horizon | 3-year (annual grants) | 5-year, vests when achieved |
| Participants | ~100 key employees (Director+) | Same |
| FCF Targets | $150M threshold / $225M target / $300M max | N/A |
| Payout | 50-200% | Binary 0% or 100% |
5d. Lessons Transferable to Phreesia
- Start with equity-heavy, below-market cash comp to signal alignment
- Premium-priced options work as sign-on/turnaround grants
- Avoid 3-year option terms — use 7-10 year terms or PSUs
- Blend stock price metrics with operational metrics from day one
- Annual grant cadence over one-time mega-grants
- rTSR protects against sector-wide moves
- PSU hurdle design matters enormously — achievable base + separate moonshot
- Keep severance lean (Senkypl renegotiated down from 12mo to 3mo)
6 Transformation Comp Benchmarks
Key Findings (~22 companies analyzed)
- 85-90% variable comp is universal for transformation CEOs
- Pure TSR is falling out of favor — best practice blends rTSR with 1-2 operational metrics
- PE pattern: equity reset at current valuation is non-negotiable; Transformation RSUs are the public-market analog
- PSU max above 200% invites trouble (PANW's 600% triggered 38% say-on-pay failure)
6a. PE-Backed Transformations
| Company | Acquirer | Outcome | Key Comp Feature |
|---|
| Athenahealth | Veritas/Elliott | $5.7B to $17B (3x) | Equity reset at entry; MOIC-based vesting |
| Informatica | Permira/CPPIB | $5.3B to $8B | Options at PE-era valuations = massive IPO upside |
| GoDaddy | KKR/Silver Lake | $2.25B to $75+ (7x+) | 40% performance / 60% time option split |
| Dell | Silver Lake/Dell | $24.9B to $100B+ (11x) | $91M retention pool; FCF as primary bonus metric |
| Solera | Vista Equity | Operational improvement | VSOP playbook; below-market base + high equity leverage |
6b. Public Market Transformations
| Company | Situation | Key Comp Feature |
|---|
| Sonos | Post-crisis recovery | 90% variable; bonus gated on quality restoration; 40% rTSR + 60% operational PSUs |
| AMD | $2B turnaround to $200B+ | Modest early comp ($6.5M); heavy equity loading; PRSUs with financial gates |
| Best Buy | Brick-and-mortar turnaround | 50% OI + 20% comp sales + 30% strategic objectives |
| Palo Alto Networks | Say-on-pay failure (38%) | Reduced PSU max 600%→400%; shifted to NGS ARR + EPS; 100% performance equity |
| PagerDuty | First GAAP profitability | 97% equity comp; $600K salary |
| Cimpress | CEO took minimum wage | 100% PSU; 6-10yr measurement; powerful signal but targets proved unachievable |
6c. Healthcare IT Peers
| Company | PSU Metrics | Bonus Metrics | Equity % | Say-on-Pay |
|---|
| HealthEquity | 75% rTSR (R2000) + 25% cum. NI/share | Revenue + EBITDA + New HSA Sales (each 33%) | 85-89% | ISS Score: 1 |
| Health Catalyst | TSR + Revenue Growth + EBITDA Margin | Not detailed | 90% | 99% |
| Evolent Health | EBITDA + Revenue + TSR modifier | EBITDA + Bookings + Fwd EBITDA | 93% | 94% |
| Intapp | ARR Growth + Operating Margin | Net New ACV + Individual | 97% | 87% |
| Phreesia (current) | 100% rTSR vs. R3000 | Revenue + EBITDA (50/50) | 95% | 91% |
6d. Universal Patterns
Cross-Cutting Findings
- Base salary: $450K-$900K regardless of size; sub-10% of total comp is universal
- Variable pay: 85-97% of total comp across all transformation companies
- PSU/RSU split: 50/50 is median; transformation companies skew 70/30 to 90/10 toward PSUs
- Bonus metrics: 2-3 metrics (PE firms use 2; best public cos use 3). Revenue/ARR (~80%), EBITDA (~75%), Transformation-specific (~50%)
- Bonus cap: 150-200% of target; HealthEquity at 200% is peer-appropriate
- Fresh equity at current prices: Every PE deal resets at entry; Transformation RSUs are the public-market analog
6e. Metrics That Work (Ranked)
| Tier | Metric | Used By | Why It Works |
|---|
| Tier 1 | Transformation-specific ARR | PANW, Teradata, Informatica, Intapp | Directly measures strategic shift |
| Tier 1 | Revenue growth + EBITDA margin | HealthEquity, Best Buy, GoDaddy | Rewards profitable growth |
| Tier 1 | Relative TSR vs. relevant index | Nokia, HealthEquity, HCAT, PHR | Market-relative alignment |
| Tier 2 | Free cash flow / FCF conversion | Dell, Vista portfolio | Capital allocation discipline |
| Tier 2 | Net revenue retention | BMC, Informatica, Teradata | Leading indicator of durability |
| Tier 2 | Stock price hurdles | Veeva, transformation grants | Clear equity story |
| Tier 3 | Quality / non-financial gates | Sonos, Best Buy | Early transformation guardrails |
6f. Comp Structures That Failed
Perceived disconnect between pay and performance. Fix: reduced max to 400%, shifted to NGS ARR + EPS, engaged 55% of shareholders. Lesson: Keep PSU max at 200-220%.
CEO took minimum wage salary, 100% PSU comp requiring 11% share price CAGR over 6-10 years. After 5 years: zero payout. Market cap CAGR: -2.54%/year. Lesson: Must have achievable threshold payouts (50% at moderate improvement).
Metrics rewarded revenue and margins but not product quality. Years of technical debt led to catastrophic app rewrite, $500M value destruction, CEO departure. Lesson: Include non-financial gates (quality, platform reliability) as bonus prerequisites.
7 AI-First Cost Optimization
Key Findings
- AI coding tools deliver 15-30% genuine productivity improvements — conservative R&D savings of $25-33M annually
- Klarna achieved 3.6x revenue/employee but quality degradation forced partial reversal — set R&D floor at 18%
- Shopify's "prove AI can't do it" hiring policy is the process-oriented model for Phreesia
- Healthcare SaaS has regulatory/compliance constraints that limit automation ceiling
7a. Case Studies
| Company | Rev/Employee | R&D % Rev | AI Strategy | Key Lesson |
|---|
| Klarna | $1.24M (3.6x growth) | — | 49% headcount cut, then course-corrected | Quality degradation forced reversal |
| Shopify | ~$750K | ~25% | "Prove AI can't do it" hiring policy | Process-oriented, culturally embedded |
| Duolingo | ~$600K | ~20% | Contractors first; 4-5x content productivity | Low-risk contractor-first approach |
| Block | ~$400K | ~15% | 40% workforce cut | Market rewarded, but was overhiring correction |
| Atlassian | ~$500K | ~25% | 10% cut (900+ R&D); $390M savings | "Self-funded AI pivot" framing |
| Phreesia | ~$262K | 28% | Target: $350K+ | 6-8pp above benchmark |
7b. AI-First Development Economics
- Average time savings: 3.6 hours/week per developer; 30-60% on coding, testing, docs
- Microsoft/Accenture: 26% average productivity gains
- NVIDIA: 30,000 engineers using Cursor, 3x productivity gains reported
- 90% of dev teams now use AI in workflows (up from 61% one year prior)
- Caveat: Senior developers actually work 19% slower on complex tasks with AI
- Caveat: AI-generated code has ~1.7x more issues than human-written code
- Net effect: Real gains are 15-20% genuine, smaller than headline 30-60%
7c. What AI Could Reduce at Phreesia
| Mechanism | Est. Annual Savings | Timeline |
|---|
| AI-assisted code generation (Copilot-class) | $10-15M | 12-24 months |
| Automated QA/testing | $3-5M | 12-18 months |
| Offshore leverage (India expansion) | $5-8M | 6-12 months |
| Product portfolio rationalization | $3-5M | 12-24 months |
| S&M: AI lead gen, automated onboarding | $10-18M | Already underway |
| G&A: Finance/legal automation, SBC restructuring | $8-15M | 6-18 months |
7d. Risks of Over-Cutting
Critical Risk Mitigations
- R&D floor at 18% of revenue. Healthcare SaaS has regulatory, compliance, and data sensitivity requirements that limit automation.
- Quality gates on efficiency metrics. If NPS or client retention declines, efficiency bonus capped at 50% of target.
- Ring-fence innovation budget. 15% of R&D for new product development, non-reducible.
- Track voluntary attrition separately. Losing A-players is a red flag — include "regrettable attrition" as negative modifier.
- "AI dividend" program. 20-30% of headcount savings flow to remaining employee comp increases (Klarna's 60% pay increase model).
8 Proposed Compensation Models
This is the core of the analysis. Three options presented — Option B (Moderate) is PFC's recommendation.
Option A: Conservative — Minimal Disruption
Philosophy: Tweak existing structure at the margins. Signal competence to Kessler without provoking management resistance.
| Element | Current | Proposed Change |
|---|
| PSU Metrics | 100% rTSR vs. R3000 | 50% rTSR vs. healthcare SaaS peers + 25% EBITDA + 25% Revenue Growth |
| PSU Peer Group | Russell 3000 | Custom 14-16 healthcare IT companies |
| Bonus Cap | 150% | 200% (aligns with HealthEquity) |
| Bonus Metrics | Revenue 50% + EBITDA 50% | Revenue 37.5% + EBITDA 37.5% + NRR 25% |
| Salary | $515K | No change |
| RSU Vesting | 10/20/30/40 | No change |
| Dimension | Assessment |
|---|
| Annual Cost | Neutral to +$1-2M |
| Dilution | Negligible |
| ISS/Glass Lewis Risk | Very low |
| Board Adoption | 70-80% |
| Honest Trade-Off | May not be enough. Doesn't create new incentive for transformation-speed efficiency gains. |
Option B: Moderate — PFC's RECOMMENDED Approach
Philosophy: Restructure incentives to reward the efficiency transformation management has already started, while adding transformation equity at current depressed prices. Frame entirely around Kessler's own HealthEquity principles.
PSU Restructuring
| Component | Weight | Measurement | Threshold (50%) | Target (100%) | Maximum (200%) |
|---|
| rTSR vs. healthcare IT peers | 40% | 3-year, 60-day VWAP | 25th percentile | 50th percentile | 75th+ percentile |
| Adj. EBITDA Margin | 30% | FY2028 (3-year cliff) | 22% | 27% | 32% |
| Revenue per Employee | 30% | FY2028 (3-year cliff) | $300K | $350K | $400K |
Why these metrics:
- rTSR at 40% (reduced from 100%) maintains market alignment while reducing pure-sentiment risk
- EBITDA margin directly incentivizes cost optimization and SBC discipline
- Revenue/employee is the best single metric for operating leverage — captures both growth and headcount discipline
- Mirrors Kessler's HealthEquity model (75% TSR + 25% operational) with heavier operational weighting
Efficiency Bonus Trigger
| Metric | Trigger | Effect |
|---|
| Revenue/Employee | Exceeds $300K | +25% on earned bonus |
| Revenue/Employee | Exceeds $350K | +50% on earned bonus |
Transformation RSUs
| Element | Detail |
|---|
| Type | Performance RSUs, one-time grant |
| Pricing | Current stock price (~$12, 60-day VWAP) |
| Stock Price Hurdles | Tranche 1: $20 | Tranche 2: $30 | Tranche 3: $50 |
| Measurement | 60-day VWAP must sustain above hurdle |
| Expiry | 5 years from grant |
| Participation | CEO, CFO, COO, SVP Life Sciences, GC + top ~45 Director+ employees |
| Total Pool | 3-4% of fully diluted shares (~1.5-2.0M shares) |
| CEO Allocation | ~0.8-1.0% of fully diluted shares |
Why Transformation RSUs Work
Stock is at $12, down 85% from $80.61 peak. Prior equity grants are largely worthless (FY2022 PSU cycle paid 53.5%). Management is sitting on years of underwater equity. Transformation RSUs at current prices give them a "second bite" — exactly what PE firms do at every take-private transaction. The $20/$30/$50 hurdles represent 67%, 150%, and 317% appreciation respectively. Ambitious but credible given $420M revenue growing 18% on a $730M market cap.
Salary & Structure Changes
| Element | Proposal |
|---|
| CEO Salary | Maintain at $515K — benchmark to 25th percentile |
| Bonus Cap | Increase to 200% (match HealthEquity) |
| Bonus Metrics | Revenue 37.5% + EBITDA 37.5% + NRR 25% |
| RSU Vesting | Shift to annual grants with 3-year cliff |
| Equity Participation | Expand eligibility to top 50 employees |
| Bonus RSU Election | Maintain — highlight as best-in-class |
Cost, Dilution & Governance
| Dimension | Assessment |
|---|
| PSU restructuring | Cost-neutral (same pool, different metrics) |
| Transformation RSUs | ~$15-25M grant-date FV (one-time, $3-5M/yr incremental SBC) |
| Efficiency bonus triggers | $0-3M/year (self-funding) |
| Net incremental annual cost | $3-9M (0-2% of revenue) |
| Dilution | 3-4% (within PE transformation norms of 5-20%) |
| ISS Risk — PSU changes | Positive |
| ISS Risk — Transformation RSUs | Moderate (one-time grants require disclosure) |
| ISS Risk — Overall | Low-to-Moderate |
| Board Adoption Probability | 45-55% |
Honest Trade-Off
Management may resist revenue/employee PSU metric as implicitly constraining hiring. Counterargument: it measures outcomes, not inputs. Risk that Transformation RSU pool is seen as excessive dilution — pre-filing engagement with top 10 holders is essential.
Option C: Aggressive — Full Transformation Redesign
Philosophy: Force the pace. Treat Phreesia like a PE take-private with public-market constraints. This is the "if we controlled the board" option.
Metric 1 (50%): Revenue reaching $1B. Metric 2 (50%): Stock reaching $50. 5-year horizon, binary (0% or 100% per metric). CEO, CFO, COO only. 1-2% of fully diluted shares.
| Year | R&D/Revenue Target | Comp Consequence |
|---|
| FY2027 | 26% (from 28%) | 25% of LTI tranche eligible |
| FY2028 | 24% | 50% eligible |
| FY2029 | 22% | 100% eligible |
Floor at 18%. If not met, corresponding LTI tranche forfeited.
Salary cut from $515K to $400K (voluntary). Equity grant increased from $5M to $8M at current prices. The salary cut is symbolic ($115K) but powerful optics — Senkypl's voluntary minimum wage drove say-on-pay from 73% to 98%.
Options: Strike at $18 (50% premium over ~$12). Quarterly vesting over 3 years. 7-year term. 500K-750K for CEO.
SBC Cap: Total company SBC cannot exceed 12% of TTM revenue. If exceeded, no new equity grants authorized. Current SBC is ~16%. This is the single most aggressive element.
| Dimension | Assessment |
|---|
| Annual Cost | $5-12M/year |
| Dilution | 4-6% fully diluted |
| ISS/Glass Lewis Risk | High |
| Management Resistance | High (70-80%) |
| Board Adoption | 15-25% |
| Honest Trade-Off | Maximizes alignment but risks co-founder departures. If Indig leaves, stock likely drops 15-20%. |
Side-by-Side Comparison
| Dimension | Option A (Conservative) | Option B (Moderate) ★ | Option C (Aggressive) |
|---|
| PSU Metrics | 50% rTSR + 25% EBITDA + 25% Revenue | 40% rTSR + 30% EBITDA margin + 30% Rev/Employee | Same as B + R&D mandate + Moonshot |
| Transformation Grants | None | Yes ($20/$30/$50 hurdles) | Yes + Premium Options + Moonshot |
| Salary | No change | No change, benchmark 25th pctile | Cut to $400K |
| Bonus Cap | 200% | 200% + efficiency kicker | 200% + efficiency kicker |
| SBC Discipline | No mechanism | Revenue/employee incentive | Hard 12% cap |
| Annual Cost | ~$0-2M | ~$3-9M | ~$5-12M |
| Dilution | Negligible | 3-4% | 4-6% |
| ISS Risk | Very Low | Low-Moderate | High |
| Mgmt Resistance | Low | Moderate | High |
| Board Adoption | 70-80% | 45-55% | 15-25% |
| Impact | Incremental | Meaningful | Maximum (if adopted) |
PFC Recommendation: Option B
It delivers the structural changes that matter (operational metrics in PSUs, efficiency incentives, transformation equity at depressed prices) without provoking the governance fight that Option C guarantees. The Kessler framing makes it defensible. The cost is modest. The risk is manageable.
9 Risk Assessment
9a. Retention Risk
Severity: High
Co-founders have 21 years at Phreesia. Their equity is largely underwater (stock down 85%; FY2022 PSUs paid 53.5%). They could be poached by PE-backed healthcare IT companies offering fresh equity.
Mitigation: Option B's Transformation RSUs directly address this. New grants at $12 give meaningful upside. The $20 hurdle (Tranche 1) is only 67% appreciation — credible and motivating.
Red line: Any proposal that appears punitive risks triggering departures. Frame as "evolving comp to match the company's new stage."
9b. Shareholder Reaction / Say-on-Pay
Current say-on-pay: 90.6%. Healthy but not bulletproof (Health Catalyst: 99%, Evolent: 94-98%). Any restructuring increasing total comp without clear performance linkage risks eroding the vote.
Mitigation: Proactive engagement with top 10 shareholders before proxy filing. Model on PANW's recovery (engaged 55% of shares after 38% failure).
9c. ISS/Glass Lewis Element-by-Element
| Element | ISS View | Glass Lewis View | Risk |
|---|
| Operational metrics in PSUs | Endorsed | Endorsed | None |
| Custom peer group | Endorsed | Endorsed | None |
| Transformation RSUs (one-time) | Scrutinized | Scrutinized | Moderate |
| Stock price hurdles | Preferred over time-only | Preferred | Low |
| Bonus cap at 200% | Within norms | Within norms | None |
| Revenue/employee in PSU | Novel but measurable | Novel but measurable | Low |
| Premium options (C only) | Requires shareholder approval | Requires approval | High |
| SBC cap (C only) | Unprecedented | No precedent | Very High |
9d. Legal/Governance Constraints
- Transformation RSU pool requires comp committee approval; may require shareholder approval if it exceeds plan limits
- Premium-priced options (Option C) require stockholder vote under NYSE rules
- CIC treatment changes require executive consent (cannot unilaterally reduce)
- 280G excise tax provisions cannot be modified without executive agreement
9e. Management Resistance Probability
| Option | Resistance | Likely Friction Points |
|---|
| A | Low (10-20%) | Management may welcome peer group narrowing and bonus cap increase |
| B | Moderate (40-50%) | Revenue/employee seen as constraining hiring; EBITDA margin PSU seen as penalizing R&D investment |
| C | High (70-80%) | R&D mandate, SBC cap, salary cut all constrain discretion; co-founders may view as hostile |
10 Engagement Strategy
10a. Four-Phase Timeline
Phase 1: Now – May 2026
Soft introduction. Engage Gandhi (CFO) informally. Present PFC's perspective on comp evolution. No formal proposal yet.
Phase 2: Apr – Jun 2026
Kessler alignment. After Kessler joins (April 6), seek informal conversation. Test receptivity to HealthEquity-style operational metrics in PSUs.
Phase 3: Jul – Sep 2026
Formal proposal. After Annual Meeting and new comp committee is seated. Submit formal proposal through Gandhi to the comp committee.
Phase 4: Oct 2026 – Jan 2027
Proxy influence. If incorporated, support proxy disclosure. If rejected, evaluate shareholder proposal for 2027 Annual Meeting.
10b. Framing Language
Do Say
- "We want to evolve Phreesia's comp to match the company's new stage — from growth-at-all-costs to profitable growth"
- "Jon Kessler's HealthEquity model is the inspiration — operational metrics alongside TSR"
- "Management has earned our confidence through the EBITDA swing — now comp should reward the next phase"
- "Transformation RSUs are a 'second bite' at current valuations — exactly what PE firms do"
Don't Say
- "Cost cutting" — use "operating leverage" or "efficiency optimization"
- "Activist" — use "engaged shareholder" or "long-term partner"
- "SBC is too high" — use "GAAP profitability gap" or "adjusted-to-GAAP reconciliation opportunity"
- "Management is overpaid" — data shows they're underpaid on realized basis
10c. Leverage Points
- SBC as % of revenue (16%). The gap between Adj. EBITDA ($37M) and GAAP operating loss (-$58M). Frame: "If SBC declines to 12%, GAAP profitability arrives 12 months sooner."
- GAAP vs. Adj. EBITDA gap. $95M in addbacks (FY2025) is harder to defend as revenue grows.
- Peer benchmarks. HealthEquity, Health Catalyst, Intapp all use operational metrics. Phreesia's 100% TSR PSU is an outlier.
- Stock vs. fundamentals. Revenue nearly doubled, EBITDA swung $130M positive, yet stock at all-time lows.
- Kessler's track record. ISS QualityScore 1 at HealthEquity. His principles are empirically validated.
10d. What NOT to Do
Critical Don'ts
- Don't propose before the committee is seated. Engaging departing members wastes political capital and may leak as hostile.
- Don't frame as punitive. Management's equity is underwater. Transformation RSUs are a carrot, not a stick.
- Don't ignore the bonus-to-RSU election. Praising it builds credibility. "PFC recognizes and applauds the CEO's voluntary conversion."
- Don't cherry-pick a low-comp peer group. ISS will flag this. Use methodology-driven approach.
- Don't demand changes to severance/CIC. These require executive consent and create adversarial dynamics. Fight the battles that matter.
11 Appendix
Full Adjusted EBITDA Reconciliation
| Item | FY2023 | FY2024 | FY2025 |
|---|
| Net Loss | ($176.1M) | ($136.9M) | ($58.5M) |
| (+) Stock-Based Compensation | $58.8M | $71.6M | $67.0M |
| (+) Depreciation & Amortization | $25.3M | $29.5M | $27.9M |
| (+/-) Other adjustments | ($0.5M) | $0.4M | $0.4M |
| Adjusted EBITDA | ($92.5M) | ($35.4M) | $36.8M |
| Adj. EBITDA Margin | -33% | -10% | +9% |
SBC by Function (Annualized Q1 FY2026)
| Function | Annualized SBC | Notes |
|---|
| G&A | ~$26.4M | Largest allocation — heavily executive comp |
| S&M | ~$20.8M | |
| R&D | ~$17.6M | |
| Cost of Revenue | ~$4.4M | |
| Total | ~$69M | 15% of guided revenue |
Capital Expenditures
| Item | FY2023 | FY2024 | FY2025 |
|---|
| Capex (PP&E) | $4.7M | $5.8M | $8.7M |
| Capitalized Software | $21.5M | $19.3M | $15.4M |
| Total Investment | $26.2M | $25.1M | $24.1M |
| as % of Revenue | 9% | 7% | 6% |
Headcount History
| Period | Employees | Change |
|---|
| FY2023 (Jan 2023) | ~1,576 | — |
| FY2024 (Jan 2024) | 1,438 | -8.8% (deliberate reduction) |
| FY2025 (Jan 2025) | ~1,500 | Modest recovery |
| Late FY2026 (incl. AccessOne) | ~2,082 | +39% (acquisition-driven) |
Margin Trajectory
| Margin | FY2023 | FY2024 | FY2025 | Q1 FY2026 | FY2026 Guide |
|---|
| Gross Margin | 61% | 65% | 68% | ~69% | ~70% |
| Adj. EBITDA Margin | -33% | -10% | +9% | +18% | +17-19% |
| FCF Margin | -34% | -16% | +2% | +6% | — |
Groupon Say-on-Pay Trajectory
| Year | Approval | Trend |
|---|
| FY2021 | ~73% | — |
| FY2022 | ~73% | Flat |
| FY2023 | ~83% | +10pp |
| FY2024 | ~98% | +15pp |
Source References
- Phreesia DEF 14A proxy statements (FY2022-FY2025)
- Phreesia 10-K/10-Q filings (SEC EDGAR)
- Phreesia Q1-Q3 FY2026 earnings presentations and stakeholder letters
- HealthEquity proxy statements (FY2021-FY2025)
- Groupon DEF 14A proxy statements (FY2022-FY2024)
- Groupon 2026 LTIP/PSU Proposal (internal, Feb 2026)
- ISS/Glass Lewis compensation evaluation frameworks
- Goodwin Procter PE compensation surveys
- Heidrick & Struggles, Korn Ferry benchmarking data
- StockAnalysis, MarketScreener, ainvest.com financial data
- Motley Fool, StockTitan, BioSpace earnings coverage
- Klarna, Shopify, Duolingo, Block, Atlassian IR & press releases
This document is PFC's internal strategy memo. It should not be shared with Phreesia management, board members, or external advisors without PFC Investment Committee approval. The engagement strategy should be executed by the designated PFC representative beginning Q2 2026.